2. Search Result
Search Result
Results for "

CC+chemokine+receptor

" in MedChemExpress (MCE) Product Catalog:

17

Inhibitors & Agonists

3

Recombinant Proteins

2

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-103364A
    C-021 dihydrochloride
    2 Publications Verification

    		 CCR Inflammation/Immunology
    C-021 dihydrochloride is a potent CC chemokine receptor-4 (CCR4) antagonist. C-021 dihydrochloride potently inhibits functional chemotaxis in human and mouse with IC50s of 140 nM and 39 nM, respectively. C-021 dihydrochloride effectively prevents human CCL22-derived [ 35S]GTPγS from binding to the receptor with an IC50 of 18 nM .
    C-021 dihydrochloride
  • HY-U00064
    AZD2098
    4 Publications Verification

    		 CCR Inflammation/Immunology Endocrinology
    AZD2098 is a potent and selective CC-chemokine receptor 4 (CCR4) inhibitor with pIC50s of 7.8, 8.0, 8.0 and 7.6 for human, rat, mouse and dog respectively, used for asthma research .
    AZD2098
  • HY-133073
    CCR7 Ligand 1
    3 Publications Verification

    CCR7-Cmp2105

    		 CCR Ligands for Target Protein for PROTAC Cancer
    CCR7 Ligand 1 (CCR7-Cmp2105) is an allosteric Ligand and antagonist for human CC chemokine receptor 7 (CCR7) with a Kd of 3 nM. CCR7 Ligand 1, thiadiazole-dioxide ligan, suppresses arrestin binding in response to activation by CCL19 with an IC50 of 7.3 μM .
    CCR7 Ligand 1
  • HY-100183
    GSK2239633A

    		CCR Inflammation/Immunology Endocrinology
    GSK2239633A is a CC-chemokine receptor 4 (CCR4) antagonist, which inhibits the binding of [ 125I]-TARC to human CCR4 with a pIC50 of 7.96.
    GSK2239633A
  • HY-101038A
    ZK756326 dihydrochloride
    1 Publications Verification

    		 CCR Endocrinology Cancer
    ZK756326 dihydrochloride is a nonpeptide chemokine receptor agonist for the CC chemokine receptor CCR8.
    ZK756326 dihydrochloride
  • HY-103364
    C-021
    2 Publications Verification

    		 CCR Inflammation/Immunology
    C-021 is a potent CC chemokine receptor-4 (CCR4) antagonist. C-021 potently inhibits functional chemotaxis in human and mouse with IC50s of 140 nM and 39 nM, respectively. C-021 effectively prevents human CCL22-derived [ 35S]GTPγS from binding to the receptor with an IC50 of 18 nM .
    C-021
  • HY-157453
    CCR4 antagonist 4
    1 Publications Verification

    		 CCR Inflammation/Immunology
    CCR4 antagonist 4 (compound 22) is a selective and potent antagonist of the CC chemokine receptor-4 (CCR4), with an IC50 of 0.02 μM. CCR4 antagonist 4 also blocks MDC-mediated chemotaxis (IC50: 0.007 μM) and Ca 2+ mobilization (IC50: 0.003 μM). CCR4 antagonist 4 can be used for allergic inflammation research .
    CCR4 antagonist 4
  • HY-112874
    BMS-681

    BMS-687681

    		 CCR Neurological Disease Inflammation/Immunology Cancer
    BMS-681 is an orthosteric antagonist of CC chemokine receptor 2 (CCR2). BMS-681 restricts the movement of the extracellular end of TM6 by stabilizing TM7. TM7 and TM6 are the main components of the orthosteric binding site. BMS-681 can be used to study inflammatory neurodegenerative diseases and cancer .
    BMS-681
  • HY-101038
    ZK 756326

    		CCR Endocrinology Cancer
    ZK756326 is a nonpeptide chemokine receptor agonist for the CC chemokine receptor CCR8.
    ZK 756326
  • HY-176980
    CCR6 antagonist 4

    		CCR Inflammation/Immunology
    CCR6 antagonist 4 (compound OXM1) is a potent and selective CC chemokine receptor 6 (CCR6) allosteric antagonist (IC50 = 158 nM). CCR6 antagonist 4 binds to an extracellular pocket and disrupts the receptor activation network. CCR6 antagonist 4 can be used for chronic inflammatory diseases research .
    CCR6 antagonist 4
  • HY-176979
    CCR6 antagonist 3

    		CCR Inflammation/Immunology
    CCR6 antagonist 3 (compound OXM2) is a potent and selective CC chemokine receptor 6 (CCR6) allosteric antagonist (IC50 = 166 nM). CCR6 antagonist 3 binds to an extracellular pocket and disrupts the receptor activation network. CCR6 antagonist 3 can be used for chronic inflammatory diseases research .
    CCR6 antagonist 3
  • HY-125836
    CCR4 antagonist 2

    		CCR Endocrinology Cancer
    CCR4 antagonist 2 (Compound 31) is a novel potent, orally bioavailable small molecule antagonists of CC chemokine receptor 4 (CCR4) that inhibits Treg trafficking into the Tumor Microenvironment without suppressing the number of Treg in healthy tissues. CCR4 antagonist 2 (Compound 31) exhibits IC50 values of Ca 2+flux and (chemotaxis) CTX are 40 nM and 70 nM, respectively .
    CCR4 antagonist 2
  • HY-163761
    LT166

    		CCR Others
    LT166 is a fluorescent ligand for CC chemokine receptor 1 (CCR1) with a KD of 1.90 μM .
    LT166
  • HY-103364AR
    C-021 dihydrochloride (Standard)

    		Reference Standards CCR Inflammation/Immunology
    C-021 (dihydrochloride) (Standard) is the analytical standard of C-021 (dihydrochloride). This product is intended for research and analytical applications. C-021 dihydrochloride is a potent CC chemokine receptor-4 (CCR4) antagonist. C-021 dihydrochloride potently inhibits functional chemotaxis in human and mouse with IC50s of 140 nM and 39 nM, respectively. C-021 dihydrochloride effectively prevents human CCL22-derived [35S]GTPγS from binding to the receptor with an IC50 of 18 nM .
    C-021 dihydrochloride (Standard)
  • HY-103364R
    C-021 (Standard)

    		Reference Standards CCR Inflammation/Immunology
    C-021 (Standard) is the analytical standard of C-021. This product is intended for research and analytical applications. C-021 is a potent CC chemokine receptor-4 (CCR4) antagonist. C-021 potently inhibits functional chemotaxis in human and mouse with IC50s of 140 nM and 39 nM, respectively. C-021 effectively prevents human CCL22-derived [35S]GTPγS from binding to the receptor with an IC50 of 18 nM .
    C-021 (Standard)
  • HY-100183R
    GSK2239633A (Standard)

    		CCR Reference Standards Inflammation/Immunology Endocrinology
    GSK2239633A (Standard) is the analytical standard of GSK2239633A (HY-100183). This product is intended for research and analytical applications. GSK2239633A is a CC-chemokine receptor 4 (CCR4) antagonist, which inhibits the binding of [125I]-TARC to human CCR4 with a pIC50 of 7.96.
    GSK2239633A (Standard)
  • HY-182564
    ST45177901

    		CCR Cancer
    ST45177901 is a CC chemokine receptor 4 (CCR4) antagonist. The combination of ST45177901 and Sorafenib (HY-10201) effectively inhibits the chemotaxis of Treg cells via the CCL22/CCL17-CCR4 signaling pathway, thereby significantly suppressing the growth and metastasis of tumor cells. ST45177901 is applicable to liver cancer research .
    ST45177901

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: